Evidence map›Paper›PMID 41889412›Full record

ArticleFrontiers in oncology2026

Correction: Siltuximab as a first-line therapy for idiopathic multicentric Castleman disease: a retrospective analysis based on the SiMuLa study of the Italian regional network.

S Pelliccia, A Di Rocco, G Palumbo, A Zizzari, O Annibali, E Maiolo, A Rago, G Trapè, M P Bianchi, G Pileggi and 8 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

S PellicciaHematology, Department of Clinical and Molecular Medicine, University Hospital Sant'Andrea - Sapienza, Rome, Italy.
A Di RoccoHematology, Department of Translational and Precision Medicine Univ Sapienza, Rome, Italy.
G PalumboHematology, Department of Translational and Precision Medicine Univ Sapienza, Rome, Italy.
A ZizzariHematology, Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy.
O AnnibaliResearch Unit of Hematology, Department of Medicine and Surgery, Università Campus Bio- Medico di Roma, Rome, Italy.
E MaioloUniversity Policlinico Gemelli Foundation-IRCCS, Catholic University of the Sacred Heart, Roma, Italy.
A RagoHematology Unit, Azienda Sanitaria Locale (ASL) ROMA 1, Rome, Italy.
G TrapèHematology Unit, Ospedale Belcolle, Viterbo, Italy.
M P BianchiHematology, Department of Clinical and Molecular Medicine, University Hospital Sant'Andrea - Sapienza, Rome, Italy.
G PileggiHematology, Department of Clinical and Molecular Medicine, University Hospital Sant'Andrea - Sapienza, Rome, Italy.
L FilomenoHematology, Department of Clinical and Molecular Medicine, University Hospital Sant'Andrea - Sapienza, Rome, Italy.
S HohausUniversity Policlinico Gemelli Foundation-IRCCS, Catholic University of the Sacred Heart, Roma, Italy.
L RigacciResearch Unit of Hematology, Department of Medicine and Surgery, Università Campus Bio- Medico di Roma, Rome, Italy.
M C CoxHematology, Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy.
M MartelliHematology, Department of Translational and Precision Medicine Univ Sapienza, Rome, Italy.
G La VerdeHematology, Department of Clinical and Molecular Medicine, University Hospital Sant'Andrea - Sapienza, Rome, Italy.
A Di NapoliPathology Unit, Sant'Andrea Hospital, La Sapienza University, Department of Clinical and Molecular Medicine, Sapienza University, Rome, Italy.
A TafuriHematology, Department of Clinical and Molecular Medicine, University Hospital Sant'Andrea - Sapienza, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.3389/fonc.2026.1762473.].

Indexed as

Castleman diseaseinterleukin-6multicentricreal-world evidencesiltuximab

Identifiers

PMID41889412
PMCPMC13014615

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.